Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ethical Drug Sales Down 0.2% in March, But Steady Despite Negative Factors: Crecon Report
May 16, 2012
- Short-Acting General Anesthetic ONO-2745/CNS 7056 Achieves Loss of Consciousness in All Patients: Ono
May 16, 2012
- Santen to Establish Presence in Market for Back-of-the-Eye Area with VEGF Trap-Eye
May 16, 2012
- Operating Profit Ratio for Pharmaceutical Wholesales at 0.32%, Improved but Still in Low Range: Top 4 Wholesalers
May 15, 2012
- Midterm Plan to Overcome Generic Versions of Actos, Setting Sights on Emerging Markets: Takeda
May 15, 2012
- Astellas to File for MDV3100 by June in Europe and US
May 15, 2012
- Takeda’s Sales Up 6.3% Driven by Nycomed Acquisition
May 15, 2012
- Otsuka HD Files for DPP-4 Inhibitor Saxagliptin
May 15, 2012
- Daiichi Sankyo: Net Profits Down 85% Due to Allowance for Potential Losses Related to Quality Problems Caused by Ranbaxy
May 15, 2012
- Otsuka HD: Pharma Sales, Profits Up; Sales of Abilify Break 400 Billion
May 15, 2012
- Eisai’s US Subsidiary Expands Exclusive Marketing Rights for Anti-Obesity Agent to 20 Countries in Americas
May 14, 2012
- Sales of Lipitor Down 6% in Fiscal Year Ended March 2012: Astellas
May 14, 2012
- Sales Force Effectiveness Japan 2012 to Be Held on July 10, 11
May 14, 2012
- Sales Up 1.6%, Vesicare Extends Global Growth: Astellas
May 14, 2012
- DSP’s Sales, Profits Down Due to Strong Yen, 1.6% Decline in Domestic Business
May 14, 2012
- DSP to Reconstruct its Business Strategy Due to Acquisition of BBI and Slow Business in North America
May 14, 2012
- The Growing Presence of Foreign-Affiliates (2)
May 14, 2012
- Struggles in US Operations Lead to 5.3% Fall in Sales, Strategic Products at Home Post 25% Rise: Shionogi
May 11, 2012
- “Figures to Look Forward to in 2013-2014” in Firm US Operations: President Teshirogi of Shionogi
May 11, 2012
- Seikagaku Licenses Domestic Marketing Rights to Kaken Pharmaceutical for Hernia Treatment SI-6603
May 11, 2012
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…